Abstract: The present invention relates to heterocyclic compounds of the formula ##STR1## in which R.sup.1 -R.sup.7, B, a and X have the meanings recited in the specification. These compounds are usable in the treatment of diseases of the rheumatoid group and for the prevention of allergically induced diseases.

Abstract: The present invention relates to heterocyclic compounds with the formula ##STR1## in which R.sup.1 to R.sup.7, B, a, and X have the meanings indicated in the specification. These compounds can be used for the treatment of diseases of the rheumatic variety and for the prevention of allergically-induced diseases.

Abstract: The invention concerns substituted pyrrole compounds and their pharmaceutical applications. The compounds of the invention are potent inhibitors of lipoxygenase and cyclo-oxygenase and therefore are suitable to treat the set of rheumatic illnesses and to prevent allergically induced ailments. The compounds have the general formula: ##STR1## where R.sup.1 denotes a C.sub.1 -C.sub.12 alkyl group, R.sup.2 denotes a hydrogen atom or a C.sub.1 -C.sub.12 alkyl group, or R.sup.1 and R.sup.2 together with the carbon atom and the nitrogen atom to which they are bound form a ring of 5 to 8 links which may contain a sulfur heteroatom or a carbonyl group and may be substituted with one or two C.sub.1 -C.sub.4 alkyl groups,each time two of the residues R.sup.3, R.sup.4 and R.sup.5 independently from one another represent a hydrogen atom, a C.sub.5 -C.sub.8 cycloalkyl group, a C.sub.1 -C.sub.12 alkyl group or an aryl group which may be substituted by one or two residues selected from a halogen atom, a nitro-, a C.sub.1 -C.

Abstract: By using a new method 2-(2-hydroxyethoxy)-ethanol ester is produced from flufenamic acid as a result of direct esterification with diol with an excess of 8-15 mol diol per mol flufenamic acid without concurrent removal of water.

Abstract: Novel diethylene glycol monoester of antirheumatically effective acids, e.g., lonazolac and diclofenac and others are disclosed which have inflammation inhibitory properties superior to the corresponding acid base forms. They may be produced through direct esterification without elimination of water and are suitable in the fight against diseases of the rheumatic complex.

Abstract: Disclosed are aqueous, stable, relatively concentrated solutions of diclofenac, which contain a mixture of propylene glycol and polyethylene glycol in defined quantitative proportions. The solutions preferably contain a local anesthetic such as lidocaine and a reducing agent as stabilizer.

Abstract: The invention relates to the use of naproxen lysinate, ketoprofen lysinate and/or diclofenac lysinate in the form of an injectable solution in the treatment of inflammations and rheumatic disorders, and to injectable solutions containing the anti-inflammatory active compound naproxen, ketoprofen or diclofenac in the form of its lysinate.

Abstract: At least one barbiturate or one of its pharmaceutically acceptable salts is combined with cinnarizine or flunarizine or one of their pharmaceutically acceptable salts to provide a hypnotic requiring lower dosages of barbiturates to produce the same effect as the barbiturate alone.